Publicaciones en VIVO

Mapa de la ciencia

MASSUTI SUREDA, BARTOMEU

Person (Active)

Positions

Profesor/a Asociado/a en CC. Salud, Medicina Clínica 2008 -

Publications
Teaching
Contact
Otro
Ver todos

supported publications or other works

selected publications

academic article
- 10(th) Congress on Lung Cancer-updates on clinical trials: goal. LUNG CANCER. 66-69. 2015
- Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 149-157. 2015
- Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study. BMC CANCER. 327-327. 2015
- Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: Long-term results of the Spanish GCR-3 phase II randomized trial. ANNALS OF ONCOLOGY. 1722-1728. 2015
- Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. ANNALS OF ONCOLOGY. 149-156. 2015
- Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study. MOLECULAR ONCOLOGY. 725-729. 2015
- First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. EUROPEAN JOURNAL OF CANCER. 1371-1380. 2015
- Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02. CANCER CHEMOTHERAPY AND PHARMACOLOGY. 319-324. 2015
- ROR1 as a novel therapeutic target for EGFR-mutant non-small- cell lung cancer patients with the EGFR T790M mutation. TRANSLATIONAL ONCOLOGY. 122-130. 2015
- Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications. CLINICAL LUNG CANCER. 431-446. 2015
- Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study. BMC CANCER. 427-427. 2013
- BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients with EGFR Mutations.. JOURNAL OF THORACIC ONCOLOGY. 295-300. 2013
- Biomarkers in lung oncology. PULMONARY PHARMACOLOGY & THERAPEUTICS. 508-514. 2013
- Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. JOURNAL OF THORACIC ONCOLOGY. 1280-1288. 2013
- Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients. LUNG CANCER. 491-497. 2013
- Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. EUROPEAN RESPIRATORY JOURNAL. 624-631. 2013
- Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. ONCOLOGIST. 947-955. 2013
- Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: Is a hemogram on day 8 essential?. LUNG CANCER. 415-419. 2013
- Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer.. JOURNAL OF TRANSLATIONAL MEDICINE. 135-135. 2013
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. LANCET ONCOLOGY. 239-246. 2013
- First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. ONCOLOGIST. 15-25. 2013
- First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study. ONCOLOGIST. 339-345. 2013
- First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 78-84. 2013
- First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. LUNG CANCER. 84-91. 2013
- Lung cancer and treatment in elderly patients: the Achilles Study. LUNG CANCER. 103-106. 2013
- Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer. EXPERT OPINION ON PHARMACOTHERAPY. 1683-1693. 2013
- Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors.. CLINICAL COLORECTAL CANCER. 200-206. 2013
- Panhipopituitarismo secundario a metástasis hipofisaria de adenocarcinoma esofágico. ENDOCRINOLOGIA Y NUTRICION. 133-135. 2013
- Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer. CLINICAL & TRANSLATIONAL ONCOLOGY. 705-711. 2013
- Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04). CLINICAL & TRANSLATIONAL ONCOLOGY. 411-418. 2013
- Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II-III rectal cancer. CLINICAL & TRANSLATIONAL ONCOLOGY. 592-598. 2013
- Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma. CANCER CHEMOTHERAPY AND PHARMACOLOGY. 75-82. 2013
- Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 1430-1436. 2013
- Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. JOURNAL OF CLINICAL ONCOLOGY. 859-865. 2013
- Predictors of long-term survival in patients with lung cancer included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy. CLINICAL LUNG CANCER. 180-186. 2013
- Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. 3138-3145. 2013
- Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. CLINICAL CANCER RESEARCH. 1160-1168. 2013
- Prognostic value of the Combination of Circulating Tumor Cells plus KRAS in patients with Metastatic Colorectal Cancer Treated with Chemotherapy Plus Bevacizumab. CLINICAL COLORECTAL CANCER. 280-286. 2013
- Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. CANCER CHEMOTHERAPY AND PHARMACOLOGY. 883-890. 2013
- Randomized phase II study of palifermin for reducing dysphagia in patients receiving concurrent chemoradiotherapy for locally advanced unresectable non-small cell lung cancer. JOURNAL OF THORACIC ONCOLOGY. 157-164. 2013
- Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: Mature results of the Spanish Lung Cancer Group 0008 study.. LUNG CANCER. 84-91. 2013
- Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study. PLOS ONE. 47345-47345. 2013
- Screening for epidermal growth factor receptor mutations in lung cancer. NEW ENGLAND JOURNAL OF MEDICINE. 958-967. 2013
- Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients. CLINICAL & TRANSLATIONAL ONCOLOGY. 727-736. 2013
- The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy. ONCOTARGET. 1572-1581. 2013
- Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. LUNG CANCER. 354-361. 2013
- Two consecutive studies using oral UFT-based chemotherapy regimens in elderly patients with advanced colorectal cancer. CLINICAL & TRANSLATIONAL ONCOLOGY. 154-158. 2013
- UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. BRITISH JOURNAL OF CANCER. 581-589. 2013
congress communication
- COMITÉ DE TUMORES TORÁCICOS: EXPERIENCIA EN EL HOSPITAL GENERAL ALICANTE DR. BALMIS. PERSPECTIVA DE UN AÑO 2024